Illumina, Inc. (NASDAQ:ILMN – Get Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 4,470,000 shares, an increase of 6.2% from the August 15th total of 4,210,000 shares. Based on an average daily trading volume, of 2,440,000 shares, the short-interest ratio is presently 1.8 days.
Wall Street Analysts Forecast Growth
ILMN has been the topic of a number of recent research reports. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their price target for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Royal Bank of Canada reissued an “outperform” rating and set a $242.00 target price on shares of Illumina in a research report on Wednesday, August 14th. Jefferies Financial Group initiated coverage on shares of Illumina in a research report on Monday, June 3rd. They set a “hold” rating and a $115.00 target price on the stock. Scotiabank reduced their target price on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research report on Thursday, August 15th. Finally, Piper Sandler reduced their target price on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average price target of $151.05.
Read Our Latest Stock Report on Illumina
Hedge Funds Weigh In On Illumina
Illumina Stock Performance
ILMN stock traded up $0.76 during trading on Wednesday, hitting $130.97. 2,219,940 shares of the company’s stock traded hands, compared to its average volume of 2,041,640. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. Illumina has a 52 week low of $89.00 and a 52 week high of $148.19. The stock has a fifty day moving average price of $124.26 and a two-hundred day moving average price of $120.54. The stock has a market capitalization of $20.86 billion, a price-to-earnings ratio of -15.98 and a beta of 1.15.
Illumina (NASDAQ:ILMN – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.12 by $0.24. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company’s quarterly revenue was down 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 earnings per share. As a group, equities analysts anticipate that Illumina will post 3.62 EPS for the current fiscal year.
About Illumina
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
- Five stocks we like better than Illumina
- What is the Australian Securities Exchange (ASX)
- This Is the Top Large-Cap Stock Insiders Are Buying
- What is a SEC Filing?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- Stock Dividend Cuts Happen Are You Ready?
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.